With an eye toward better matching its targeted therapeutics to the patients who will benefit most, Incyte has turned to Agilent Technologies to develop companion diagnostics for its drugs. The duo ...

DelveInsight's Companion Diagnostics Market Insights report provides the current and forecast market analysis, individual ...

Pharmaceutical companies are keen to have a stake in the personalized medicine market, viewed as a growing trend in the future of healthcare and a significant source of life science innovation. As ...

Never has there been more information to enable a patient’s fight against cancer, but how does one select the right treatment? This is how companion diagnostics fit with precision medicine. Advances ...

Personalized medicine is continuing to evolve to the point where we have drug makers developing drugs that come with a companion diagnostic, developed with the help of a diagnostic partner. Arno ...

- The DRP®-Dovitinib companion diagnostic demonstrated an ability to identify advanced renal cell carcinoma patients that have improved clinical benefit from dovitinib treatment, as compared to ...

The FDA has bestowed a green light to a companion diagnostic for Pfizer’s recently approved hemophilia B gene therapy—because, at a cost of $3.5 million per dose, you want to make sure it will work.

Companion diagnostics in fields like oncology are well-known, but it’s their potential impact on psychiatry that is gaining attention and has the potential to shape the future of the industry.

NEW YORK, Aug. 8, 2024 /PRNewswire/ -- The global companion diagnostics market size is estimated to grow by USD 28.98 billion from 2024-2028, according to Technavio. The market is estimated to grow at ...

CellCarta, a global CRO laboratory to the biopharmaceutical industry, has appointed Ehab A. El-Gabry, MD, as Chief Medical ...